Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (Q44732903)

5 December 2017

Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

5 December 2017

0 references

1 reference

1 reference

8

1 reference

5 December 2017

9

1 reference

5 December 2017

Guy Hubens

6

0 references

Luc Van Gaal

10

object named as

Luc Van Gaal

1 reference

5 December 2017

An Verrijken

1

1 reference

5 December 2017

Sven Francque

2

1 reference

5 December 2017

Ilse Mertens

3

1 reference

5 December 2017

Janne Prawitt

4

1 reference

5 December 2017

Sandrine Caron

5

1 reference

5 December 2017

Eric Van Marck

7

1 reference

5 December 2017

language of work or name

English

0 references

publication date

8 November 2013

1 reference

5 December 2017

1 reference

5 December 2017

59

1 reference

5 December 2017

1

1 reference

5 December 2017

121-129

1 reference

Nonalcoholic fatty liver disease: pathology and pathogenesis

5 December 2017

1 reference

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages

21 January 2018

1 reference

Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications

21 January 2018

1 reference

Portal vein thrombosis, cirrhosis, and liver transplantation.

21 January 2018

1 reference

Idiopathic noncirrhotic portal hypertension.

21 January 2018

1 reference

Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy

21 January 2018

1 reference

Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease.

21 January 2018

1 reference

Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome

21 January 2018

1 reference

Histopathology of non-alcoholic fatty liver disease

21 January 2018

1 reference

Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis

21 January 2018

1 reference

Updated definitions of healthy ranges for serum alanine aminotransferase levels

21 January 2018

1 reference

Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings

21 January 2018

1 reference

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

The metabolic syndrome--a new worldwide definition

21 January 2018

1 reference

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

21 January 2018

1 reference

Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Ph

21 January 2018

1 reference

Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases

21 January 2018

1 reference

Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue

21 January 2018

1 reference

Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy

21 January 2018

1 reference

21 January 2018

PAI-1 in tissue fibrosis

1 reference

Obesity, haemostasis and the fibrinolytic system

21 January 2018

1 reference

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

21 January 2018

1 reference

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

Evidence for a relationship between plasminogen activator inhibitor-1 and gamma glutamyl transferase

21 January 2018

1 reference

7 January 2021

NASH predicts plasma inflammatory biomarkers independently of visceral fat in men

1 reference

7 January 2021

Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis

1 reference

7 January 2021

Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease

1 reference

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

7 January 2021

The influence of laboratory-induced MELD score differences on liver allocation: more reality than myth.

1 reference

7 January 2021

Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease

1 reference

7 January 2021

Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.26510

1 reference

5 December 2017

1 reference